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The development and implementation of the extremely sensitive
polymerase chain reaction (PCR) has given a great impetus to the
detection of minimal loads of tumour cells in metastatic target
organs or in the blood of patients (Johnson et al, 1995; Keilholz
et al, 1997). For various solid tumours, mRNA of differentiation
antigens can be specifically amplified by a reverse transcriptase
PCR (RT-PCR). RT-PCRs have been developed for differentiation
antigens such as prostate specific antigen (PSA) in prostate cancer
(Brandt et al, 1996), cytokeratins (Schoenfeld et al, 1994) and
carcinoembryonic antigen (CEA) (Mori et al, 1995) in epithelial
cancers, and tyrosine hydroxylase in neuroblastoma (Burchill et al,
1994). Since these mRNAs are not expressed in either peripheral
blood or in target organs of the metastatic process, the detection of
these mRNAs is indicative for the presence of tumour cells.
A highly specific and sensitive RT-PCR detecting transcripts
of the melanin synthesis enzyme tyrosinase which is specifically
expressed in melanocytes and melanoma cells, was described by
Smith and co-workers in 1991 (Smith et al, 1991) and has since
then been used by various groups to detect melanoma cells in
blood of patients with a sensitivity in the range of 1 cell of a
melanoma cell line per 105–106 mononuclear cells. It was soon
reported that the detection of tyrosinase transcripts correlated
with the stage of disease (Brossart et al, 1993; Kunter et al, 1996;
Mellado et al, 1996). Also, patients with presence of melanoma
cells in the blood were shown to have a shortened survival (Kunter
et al, 1996; Mellado et al, 1996). A further increase in sensitivity
was found when not only the conventional tyrosinase RT-PCR was
performed, but also RT-PCRs for other melanoma markers on the
same blood sample (Hoon et al, 1995).
Despite these paramount achievements, various pitfalls were
encountered in the detection of tyrosinase transcripts by RT-PCR in
the blood of melanoma patients. First, the range of tyrosinase-posi-
tive blood samples in stage IV melanoma patients varied dramati-
cally between 0 and 100% (Brossart et al, 1993; Foss et al, 1995;
Kunter et al, 1996; Pittman et al, 1996; Van der Vel-de-Zimmerman
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not different in blood samples in which a melanoma marker was not detected from groups in which this marker was detected more or less
consistently (1–4 times). When applying real-time quantitative PCR for tyrosinase and MART-1, we found that a low amount of SK-MEL-28
cell equivalents was present in the blood of melanoma patients, with a higher number of equivalents in the group with a consistently positive
result. We conclude that low reproducibility of a repeated assay for the detection of circulating melanoma cells is not caused by differences in
mRNA quality between the samples, but due to low numbers of amplifiable target mRNA molecules in the mRNA sample. Use of more than
one marker and repetition of the assay will increase the probability of finding positive PCR results.
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et al, 1996; Glaser et al, 1997; Jung et al, 1997). Second, in a recent
EORTC quality control study, the reproducibility of the detection of
tyrosinase transcripts in blood samples which were spiked with
known amounts of melanoma tumour cells was poor, with three out
of seven participating study groups scoring false positive results
(Keilholz et al, 1998). Third, when taking various blood samples
from one patient on one day, only some of them were found positive
(Reinhold et al, 1997). Fourth, results from two blood samples taken
at the same time were hardly reproducible (Farthmann et al, 1998).
These results indicate that RT-PCR is not the reliable technique of
which highly reproducible and accurate results can be expected.
We previously reported that tyrosinase and another melanocytic
lineage marker, MART-1, were heterogeneously expressed in 105
cutaneous melanocytic lesions (De Vries et al, 1997). In the present
quality control study, we report in-depth on the reproducibility of the
RT-PCR technique for these markers using the same RNA sample.
Nested RT-PCRs for tyrosinase and MART-1 were performed four
times on 106 blood samples of 68 melanoma patients. Quantitative
PCRs enabled us to evaluate the quality of the mRNA samples and
the quantity of tyrosinase and MART-1 transcripts.
MATERIALS AND METHODS
Patients
At the time of blood sampling, 106 blood samples from 68 patients
with cutaneous melanoma were clinically classified according to the
AJCC/UICC criteria, stages I–IV. Thus, stage I: primary melanoma
≤ 1.5 mm and/or Clark ≤ III; stage II: primary melanoma >1.5 mm
and/or  ³ Clark IV and/or satellite metastases ≤2 cm from the
tumour; stage III: regional lymph node metastases and/or in-transit
metastases >2 cm from the primary tumour; stage IV: distant metas-
tases. Oral consent was given by the patients after brief information
on the purpose of the blood sampling. PCR outcome did not have
any consequences on the treatment regime of the patients. To avoid
possible contamination with cutaneous melanocytes, in each patient
the first tubes were used for clinical purposes and the last tube was
used for the RNA extraction and PCR analyses.
Furthermore, blood was taken from ten persons who had no
history of melanoma. These ten blood samples were from healthy
volunteers (four), dermatology patients with benign melanocytic
lesions (two) and patients with non-melanoma malignancies (four:
two patients with adenocarcinoma of the kidney, one with small
cell lung carcinoma and one with testicular carcinoma).
Blood collection and RNA isolation
Blood from melanoma patients and blood from persons with no
history of melanoma was collected in 5-ml citrate tubes (Vacutainer
brand blood collection tubes, Becton Dickinson, Franklin Lanes, NJ,
USA). After centrifugation, the plasma was removed and replaced by
a same volume of guanidinium isothiocyanate (GITC) solution
containing b-mercaptoethanol to prevent RNA degradation during
storage. The samples were snap-frozen in liquid nitrogen and stored at
–80°C. Precautions (gloves, sterile plastic ware, DEPC-treated solu-
tions) were taken to avoid RNAase contamination. RNA from blood
samples was isolated using the GITC method (Chomczynski and
Sacchi, 1987) which was previously successfully used in a similar
setting (Brossart et al, 1993, 1995). A further purification was
obtained with the RNAzol B method (Campro Scientific, Veenendaal,
The Netherlands) following the manufacturer’s instructions.
Reverse transcription
Two micrograms of total RNA were used for RT. A mixture of
RNA and 50 pmol oligodeoxynucleotide triphosphate was incu-
bated for 5 min at 65°C and then immediately put on ice, where
the other reagents were added. Altogether, the RT took place in a
volume of 20-ml RT-buffer (50 mM Tris–HCl, pH 8.3) containing
75 mM potassium chloride, 3.0 mM magnesium chloride, 10 mM
dithiothreitol, 200 mM of each nucleotide, 20 U RNAsin (Promega,
Madison, WI, USA) and 200 U MMLV reverse transcriptase
(Promega, Madison, WI, USA). After an initial incubation of
10 min at 25°C, the RT took place for 60 min at 42°C. Per incuba-
tion, 80 ml distilled water were added. From this mixture, 5 ml
were used for each PCR, equal to 100 ng reverse transcribed RNA,
hereby avoiding the pipetting of small volumes.
Polymerase chain reaction
Each PCR reaction contained 75 mM Tris–HCl, pH 9.0, and 20 mM
(NH4)2SO4, 0.01% Tween (w/v), 1.0 mM magnesium chloride, 220
mM of each nucleotide and 50 pmol of each specific primer (only in
the case of PBGD PCR, 30 pmol primer was used), 0.2 U
Thermoperfectplus DNA polymerase (Integro, Zaandam, The
Netherlands) and 0.1 mg of reverse transcribed RNA. A hot start
was used, the mixture excluding the reverse primer, the dNTPs,
and the DNA polymerase was heated for 5 min at 94°C, after
which the remaining mixture was added per vial at 80°C. A PCR
for the low copy housekeeping gene phorbobilinogen deaminase
(PBGD) was included as a control for the amplifiability of cDNA.
PBGD was amplified for 30 cycles of 0.5  min at 94°C followed
by 1.5 min at 60°C. The tyrosinase and MART-1 PCRs were
performed for 60 cycles of 0.5 min at 94°C followed by 1.5 min at
60°C followed by a nested PCR (5 ml, or 10% from the first PCR
volume, was reamplified in 50 ml of a new PCR mixture) for 30
cycles at the same conditions. In the case of tyrosinase, the primers
of the first PCR were HTYR1 and HTYR2, the nested reaction
was performed with HTYR3 and HTYR4. These primers were
used previously (Smith et al, 1991). For the detection of MART-1,
we used MART1–1 and MART 1–4 as primers for the first PCR
and melanA1 and melanA2 for the nested PCR (Table 1). In order
to avoid contamination, no hot start preceeded the 30 cycles of
nested PCR.
Quality control aspects
In the present study, each step of the RT-PCR procedure was moni-
tored (Table 2). Negative control blood samples were used from
the RNA isolation through the whole procedure. Special precau-
tions were taken to avoid contamination. These included: separate
rooms for RNA isolation, first PCR, the nested PCR and the
analysis of PCR products. Separate laboratory clothing was used
in the pre- and post-PCR handling laboratories. Vials with PCR
product were never opened in the pre-PCR laboratories. As a
control for sensitivity of the assay, we made aliquots of RNA
isolated from blood of a healthy donor which was spiked with the
RNA equivalent from 1000, 500, 100, 50, 10, 5 and 1 SK-MEL-28
cells, which produces both tyrosinase and MART-1 (De Vries et al,
1997) and which has been used before in the literature to quanti-
tate melanoma cells in the peripheral blood of melanoma patients
(Brossart et al, 1995). Thus, aliquots were obtained with 1000 to 1
cell SK-MEL-28 per ml blood. Aliquots from this series were usedRepetition of tyrosinase and MART-1 RT-PCR 885
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Table 1 Oligomeric sequences used as primers and probes
Target Primers Sequencea S/AS/Pb Product size
PBGD PBGD-5¢ 5¢-CTGGTAACGGCAATGCGGCT-3¢ S 339 bp
PBGD-3¢ 5¢-GCAGATGGCTCCGATGGTGA-3¢ AS
PBGD 5¢-CGAATCACTCTCATCTTTGGGCT-3¢ P
Tyrosinase HTYR1 5¢-TTGGCAGATTGTCTGTAGCC3¢ S 284 bp
HTYR2 5¢-AGGCATTGTGCATGCTGCTT-3¢ AS
HTYR3 5¢-GTCTTTATGCAATGGAACGC-3¢ S 207 bp
HTYR4 5¢-GCTATCCCAGTAAGTGGACT-3¢ AS
HTYR 5¢-TTACGGCGTAATCCTGGAAACCA-3¢ P
MART-1 MART1-1 5¢-ATGCCAAGAGAAGATGCTCAC-3¢ S 384 bp
MART1-4 5¢-AGCATGTCTCAGGTGTCTCG-3¢ AS
melanA1 5¢-CACTCTTACACCACGGCTGA-3¢ S 300 bp
melanA2 5¢-AGGTGAATAAGGTGGTGGTGA-3¢ AS
MART 5¢-CACAAGAAGGGTTTGATCATCGG-3¢ P
aFrom published sequences,bS = sense primer, AS = antisense primer, P = probe used with real-time PCR. Each probe contained a TET (tetrachloro-6-carboxy-
fluorescein) reporter dye at the 5¢ nucleotide and a TAMRA (6-carboxy-tetramethyl-rhodamine) quencher dye at the 3¢ nucleotide.
Table 2 Quality control aspects used in this study for the detection of melanoma marker transcripts in 106 blood samples of 68 melanoma patients
Quality control aspect Technical implication
Quality of mRNA Integrity of RNA on agarose gel
Amplification of low copy household gene PBGD
Quantitative RT-PCR for PBGD
Control of contamination Inclusion of negative control blood samples at sample preparation at each PCR round
Special separation (separate rooms) for (i) RNA isolation/cDNA synthesis, (ii) PCR product analysis, (iii) laminar
airflow cabinet for nested PCR
Separate laboratory clothing for pre- and post-PCR handlings
PCR product can never reach the sample preparation laboratory
Sensitivity of the assays Nested PCR
Inclusion of two melanoma markers
Inclusion of a spiked blood sample with minimal amount (1 cell per ml blood) of melanoma cell line in each PCR
Quantitative PCR assays for tyrosinase and MART-1
Reliability of the assays Inclusion negative controls at the final handling steps, from RNA isolation to (nested) PCR analysis
Repetition (4 times) of the experiment and comparison of the results
Table 3 Patient characteristics according to stage
Stage Number of patients Number of blood samples
Controls 10 10
Melanoma
I3 5
II 1 1
III 13 27
IV 51 73
Melanoma total 68 106
Table 4 PCR results in 116 blood samples per stage of melanocytic tumour progression
Stage Tyrosinase + (%)a MART-1 + (%)a Tyrosinase and/or MART-1 + (%)b
Controls 0/10(0%) 0/10(0%) 0/10 (0)
I 2/5 (40%) 2/5 (40%) 2/5 (40%)
II 0/1 (0%) 0/1 (0%) 0/1 (0%)
III 4/27 (15%) 5/27 (19%) 8/27 (30%)
IV 15/73 (21%) 29/73 (40%) 33/73 (45%)
aA sample was called positive when at least one out of four reactions was positive. bAt least one positive reaction out of eight determinations (four times
tyrosinase, four times MART-1).886 TJ de Vries et al
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in each reverse transcription with the same enzyme mixture as
used for the melanoma blood samples to be analysed. We deliber-
ately titrated RNA from the cell line to RNA from blood (in stead
of titrating cells to blood before the isolation), since tyrosinase and
MART-1 proteins are heterogeneously expressed in this cell line
(De Vries et al, 1997).
Experimental set-up
A reverse transcription of the mRNA of each blood sample was
performed twice. A total of 0.1 mg RNA (= 5 ml) was used for each
PCR. From each reverse transcription mixture, at least six PCRs
were performed: both tyrosinase and MART-1 in duplicate, PBGD
once with the conventional PCR, and once in real-time quantita-
tive PCR. Therefore, per blood sample, from the two RT-reactions,
four tyrosinase and four MART-1 results were obtained. A blood
sample which was positive for a melanoma marker in at least one
out of four analyses, was called positive for that marker. Each
blood sample which was positive at least once for either tyrosinase
or MART-1, was analysed in the real-time quantitative PCR as
well. Since the group of 106 blood samples and the ten control
samples was too large to handle and analyse at once, the group was
analysed in four series. In each PCR of a series, the samples spiked
with melanoma cell line SK-MEL-28 served as an interexperiment
control for sensitivity. Some blood samples which were negative
four times in the first analysis were also analysed in real-time
PCR.
Real-time quantitative RT-PCR assay
We quantitated the PBGD housekeeping gene and tyrosinase and
MART-1 transcripts by a real-time analysis (Higuchi et al, 1993;
Livak et al, 1995) using the 5´ nuclease assay (TaqmanTM) (Holland
et al, 1991) and the Abi Prism 7700 sequence detector (Perkin-
Elmer, Foster City, CA, USA) (Gibson et al, 1996; Heid et al, 1996).
In this system, PCR products are quantified by the application of a
non-extendible dual-labelled probe. This probe contains at 5´ fluoro-
genic reporter group tetrachloro-6-carboxy-fluorescein (TET) and
an internal or 3´ fluorogenic quenching group 6-carboxy-tetra-
methyl-rhodamine (TAMRA). Laser-induced excitation of intact
probe results in fluorescent energy transfer from the reporter group
to quenching group, resulting in low overall reporter group emis-
sions. During specific amplification, hybridized probe is degraded
by the nuclease activity of Taq polymerase. The increase in reporter
group emissions is proportional to the amount of PCR product
formed. Sample positivity is defined at the cycle number at which
emitted fluorescence exceeds the ten times standard deviation of
baseline emissions and is called the threshold cycle (Ct). The Ct is
proportional to the initial number of target molecules (Higuchi et al,
1993; Livak et al, 1995), and is used in the quantitative analysis.
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Figure 1 Amplification of PBGD mRNA in 19 blood samples of melanoma
patients. Blood samples were subjected to RNA isolation and RT-PCR with
primers specific for PBGD. PCR products were subsequently visualized on
an ethidium bromide stained agarose gel. Note the intensity differences
between the samples. An equal amount of cDNA (100 ng) was put in each
PCR reaction. M = 50-bp marker
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Figure 2 Amplification of tyrosinase mRNA in 19 different patient samples
and in spiked blood samples. Upper row in both panel A and B displays the
first round of PCR with a specific PCR product of 284-bp, the lower half of
both photographs shows the PCR product of 207-bp after nested PCR. The
patient samples are shown in panel A. PCR results of 19 blood samples of
melanoma patients are in lanes 1–19. Note that two out of 19 (both stage IV)
patients show a positive PCR result after the first round (though the band in
lane 6 is faint) and after the nested PCR. In panel B, the sensitivity test with
blood spiked with the tyrosinase-positive melanoma cell line SK-MEL-28 is
shown. Lane 1: 1000 cell SK-MEL-28; lane 2: 500; lane 3: 100; lane 4: 50;
lane 5: 10; lane 6: 5; lane 7:1; lane 8: no SK-MEL-28 cells added. (C) Water
control, M = 50-bp marker. Stages of patients in panel A: stage III (lanes 1–3,
8, 13), stage IV (lanes 4–7, 9–12, 14–19)
Table 5 Reproducibility of the RT-PCRs for tyrosinase and MART-1 in 106
melanoma patient blood samples (stage I–IV)
Number of positive reactions Tyrosinase + MART-1+
08 5 7 0
11 3 2 2
24 3
30 4
44 7Repetition of tyrosinase and MART-1 RT-PCR 887
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Quantification of PBGD, tyrosinase and MART-1
transcripts
In order to compare the amplifiability of mRNA isolated from
blood of melanoma patients, we performed a quantitative PCR for
a low copy housekeeping gene PBGD. This test was performed in
duplicate (two reverse transcriptions per mRNA sample) on each
mRNA sample of the 106 melanoma patients.
The amount of tyrosinase and MART-1 transcripts present in the
blood of melanoma patients could be expressed in SK-MEL-28
cell equivalents, since the dilution series with 1 to 1000 SK-MEL-
28 cells per ml blood was included in each series that we tested
with quantitative PCR. In each series tested, a standard curve
could be made (Ct versus number of cells) from the SK-MEL-28
cell equivalents. Obviously, the 1000 cell sample was detected first
(lowest Ct), the 1 cell sample last (highest Ct). The 50-ml reaction
mixture for each quantitative PCR contained 5 ml (0.1 mg cDNA)
from the reverse transcription reaction, TaqMan buffer II (10 mM
Tris–HCI pH 8.3) containing 50 mM potassium chloride, 10 mM
EDTA, 60 nM ROX), 2.5 mM magnesium chloride for the PBGD
PCR and 2.0 mM magnesium chloride for MART-1 and tyrosinase
PCRs, 200 mM of each nucleotide, 50 pmol of each specific primer
(30 pmol for PBGD primers), 10 pmol of probe (15 pmol for
PBGD probe), and 1.25 U of AmpliTaq Gold DNA polymerase
Perkin-Elmer, Foster City, CA, USA). All probes contained TET
as reporter dye at the 5¢ end and TAMRA as quencher dye at
the 3´ end. Tyrosinase was amplified using primers HTYR 1 and
HTYR4, and MART-1 was amplified using primers MelanA1
and MelanA2 (see Table 1 for sequences).
PCR conditions were the same for all targets: 10 min at 95°C (to
activate Taq polymerase) followed by 30 at 95°C and 1 min at
60°C for 60 cycles.
Statistical analysis
Statistical analysis was performed on the patient characteristics
and test outcomes of tyrosinase and MART-1. The 106 blood
samples were from 68 patients. To avoid confounding in the statis-
tical analysis, formal statistical testing was restricted to the results
of the first blood sample of each patient. Fisher’s exact test was
used to compare percentages of positive outcomes between stages.
McNemar’s test was used to compare tyrosinase and MART-1 test
results.
RESULTS
Patient characteristics
Blood samples were collected at the University Hospital Nijmegen
between November 1994 and July 1997. Initially, 115 blood
samples from melanoma patients were analysed. Nine samples
could not be used for this study due to poor mRNA quality or
wrong anticoagulant used (heparin in stead of citrate buffer).
When there was no amplification of PBGD after 40 cycles with
real-time PCR (see below), the mRNA sample was excluded from
the analysis.
Of the 68 patients, 41 were male and 27 female. Average age
was 51.2 years, range 15.7–92.2 years. From 43 patients, one
blood sample was available, from 15 patients two blood samples,
from seven patients three samples, and from three patients four
samples. The stage characteristics of the 68 patients and the
number of blood samples used in this study are shown in Table 3.
From the 25 patients with more than one blood sample, only four
progressed (one patient stage II to III, three patients stage III to
IV); the various blood samples of the other 21 patients were all in
the same stage of disease. Our patient group contained mainly
stage III and stage IV patients.
Reproducibility of four tyrosinase and MART-1 RT-PCR
determinations
A sensitive RT-PCR for the detection of a low copy household
gene PBGD was used as a control for amplifiability of mRNA
(Figure 1). Differences in mRNA amplifiability among the blood
samples were encountered.
A nested RT-PCR for both melanocytic markers, tyrosinase and
MART-1, was performed on all 106 blood samples and on ten
384 bp
300 bp
384 bp
300 bp
M C1 12345678
B
A
11 9 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2M
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Figure 3 Amplification of MART-1 mRNA in 19 different patient samples
and in spiked blood samples. Upper row in both panel A and B displays the
first round of PCR with a specific PCR product of 384 bp, the lower half of
both photographs shows the PCR product of 300 bp after nested PCR. The
patient samples are shown in panel A. PCR results of 19 blood samples of
melanoma patients are in lanes 1–19. Note that three out of 19 patients (all
stage IV) show a positive PCR result after the first round and after the nested
PCR. In panel B, the sensitivity test with blood spiked with the MART-1-
positive melanoma cell line SK-MEL-28 is shown. Lane 1: 1000 cell SK-MEL-
28; lane 2: 500; lane 3: 100; lane 4: 50; lane 5: 10; lane 6: 5; lane 7: 1; lane
8: no SK-MEL-28 cells added. C1: water control which was included in the
reverse transcription, C2: water control as a control for the nested PCR, M =
50-bp marker. Stages of patients in panel A: stage 0 (lanes 11 and 16), stage
II (lane 3), stage III (lanes 13, 15, 18, 19), stage IV (lanes 1, 2, 4–10, 12, 14,
17)888 TJ de Vries et al
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negative control samples (non-melanoma cancer patients, healthy
volunteers, dermatology patients). Both for tyrosinase and MART-
1, the PCR was performed fourfold: cDNA was made in duplicate
from each RNA sample, each cDNA sample was tested in dupli-
cate for tyrosinase and MART-1. The visibility of a PCR-band
after nested PCR was scored as a positive result. In Figures 2 and
3, the results for both PCRs in 19 blood samples are shown. As a
quality control for sensitivity, a dilution of SK-MEL-28 (a
melanoma cell line which is positive for both markers) mRNA was
included in each experiment. The sample spiked with 1 cell SK-
MEL-28 per ml blood was always detectable after nested PCR in
each group of blood samples (for practical purposes the 106 blood
samples were analysed in four groups). All ten negative controls
were 80 times negative (4 ´ 10 = 40 tyrosinase and 4 ´ 10 = 40
MART-1 determinations).
In Table 4, the results are summarized per stage of disease. In
this Table, the results per blood sample were scored positive when
at least one out of four reactions was positive for the melanoma
marker. It can be read from Table 4 that MART-1 is more often
detected than tyrosinase. When properties of positive outcomes of
first blood samples (tyrosinase, MART-1) were compared with
McNemar’s test, MART-1 was more sensitive both in stage III and
stage IV patients (McNemar’s test, P = 0.019 and 0.039 in stage III
and stage IV patients respectively). Table 4 also shows that usage
of more than one marker increases the sensitivity of detection (see
stage III and IV patients in the last column of Table 4). In our
patient group, the finding of a positive PCR result was not associ-
ated with stage of disease for tyrosinase or MART-1 separately, but
when either tyrosinase or MART-1 positivity was taken into
account, the probability of at least one melanoma marker-positive
outcome correlated with stage of disease (Fisher’s exact test on the
first blood sample of each patient, P = 0.646, 0.078 and 0.022 for
tyrosinase, MART-1 and the combination of the two markers
respectively). Since the majority of the blood samples concerned
stage III and IV samples, we also tested separately for these
two stages. Again, a positive test for tyrosinase or MART-1 alone
did not significantly correlate with stage of disease, but the finding
of at least one melanoma marker correlated positively with stage
of disease (Fisher’s exact test, P = 0.432, 0.062 and 0.028
respectively).
Since patients with stage III melanoma have a high risk for
recurrence, it was of interest to examine whether RT-PCR results
might be predictive of relapse. Of the 13 patients with stage III
disease, seven relapsed and six remained disease-free after a
median follow up of 17 months (range 10–31). Of the seven
patients who subsequently relapsed, three were positive for tyrosi-
nase/MART-1 RT-PCR at the time that stage III disease was diag-
nosed. All six disease-free patients tested negative for tyrosinase
and MART-1. Thus, a sensitivity of 3/7 and a specificity of 6/6 was
obtained in this rather small group of stage III patients.
We performed each melanoma marker PCR four times per
sample. In Table 5, the reproducibility of the assay for 106
melanoma samples is presented. This Table shows that the
majority of the blood samples was negative for tyrosinase (80%)
or MART-1 (66%). In a reliable assay, a result should be repro-
ducible in at least four different tests in the same sample. In our
study, this was found in 89/106 (84%) when using tyrosinase as
assay and in 77/106 (73%) in the case of MART-1 (Table 5). A
relatively large number of blood samples was only once positive,
and some samples twice or three times. From Table 5, it can be
deduced that 37 (13 ´ 1 + 4 ´ 2 + 0 ´ 3 + 4 ´ 4) out of 424 (106 ´
4), or 8.7%, of the tyrosinase reactions were positive. From these
37 tyrosinase positive reactions, 27 (73%) were detectable on
ethidium bromide stained agarose gel after one round of 60 cycles
of PCR. Similarly, it can be deduced that 68 (22 ´ 1 + 3 ´ 2 + 4 ´
3 + 7 ´ 4) out of 424, or 16.0%, of the MART-1 reactions were
positive. From these 68 MART-1-positive reactions, 51 (75%)
were detectable after one round of 60 cycles of PCR. Two out of
seven consistently MART-1-positive samples were consistently
negative for tyrosinase.
Real-time quantification of PBGD, tyrosinase and
MART-1 transcripts
The low reproducibility (number of positive reactions 1–3 in Table
4) and low percentage of positive results in stage III and IV
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Figure 4 Ct values of PBGD PCR in blood samples which were 0–4 times positive for tyrosinase (A) or MART-1 (B). The exact number of dots per category
correspond to the numbers in Table 5. No statistical differences were detected between samples which were 0 or 4 times positive for MART-1Repetition of tyrosinase and MART-1 RT-PCR 889
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patients can be explained by two factors: (a) the quality of mRNA
is poor in stage III and IV patients which were four times negative
compared to patients which scored four times a positive result, (b)
the quality of mRNA is good, but the amount of circulating tumour
cells, and therefore the number of specific target mRNA copies, is
very low.
We addressed these possibilities with a real-time quantitative
RT-PCR. Quantification of this PCR is based on measurements in
the linear part of the amplification curve. Thus, when measuring a
household gene like PBGD, the amplification in samples with
good quality mRNA is first detected, at a low threshold cycle
number (Ct). We performed the housekeeping gene PCR for all
106 blood samples twice, once for each reverse transcription reac-
tion. Encouragingly, the Ct-values of the two determinations were
strikingly similar. The average PBGD value of the first RT was
35.8, with a standard deviation (s.d.) of 1.8, the average PBGD
value of the second RT was 36.8, with a s.d. of 2.0 Although a Ct
difference of 1.0 (= 1.0 PCR cycle) was found between the two
RT-reactions, the 68 values (first blood sample of each patient) of
the two paired measurements strongly correlated (Spearman corre-
lation coefficient = 0.76, P = 0.0001). The average of the two
PBGD determinations was 36.3 (s.d. 1.8, range between 32.2 and
40.0). In Figure 4, the average of the two PBGD Ct values of the
106 blood samples is plotted against the number of positive tyrosi-
nase and MART-1 findings. We found no statistically significant
differences in mRNA quality between samples which were 0, 1, 2,
3, or 4 times positive (Figure 4) (one-way ANOVA test, P =
0.1560 and 0.6947 for tyrosinase and MART-1 respectively; only
first blood samples were statistically tested).
Since the quality of mRNA is not significantly different
between the blood samples which were consistently negative and
the blood samples which were consistently positive, we then
addressed the question whether the samples in which tyrosinase
and MART-1 could be detected consistently contained more SK-
MEL-28 cell equivalents (Figure 5). Since the majority of tyrosi-
nase-positive (73%) and MART-1-positive (75%) samples was
already detected after 60 cycles of PCR, we used 60 cycles of a
quantitative PCR for tyrosinase and MART-1 to address this ques-
tion. In this test, we selected 47 blood samples which included all
blood samples that were positive at least once with either tyrosi-
nase or MART-1 RT-PCR (Table 5). We also included a number of
samples that were 4 times negative. A standard curve (Ct vs SK-
MEL-28 cell number) was made from the SK-MEL-28 cell mRNA
diluted in mRNA from a healthy volunteer. As could be expected,
the 1000 cell equivalent sample was detected first (thus had the
lowest Ct value), then the 500, 100, 50, 10, 5 and 1 cell equivalent
sample respectively. All 16 standard curves (two markers, two RT-
reactions, four groups, 2 ´ 2 ´ 4) had a correlation coefficient
above 0.95 (result not shown).
Positive measurements from the samples were expressed
according to this standard curve. All negative control samples
remained negative after 60 cycles of PCR, positive signals were
never detected after 45 cycles. We found that very low numbers of
SK-MEL-28 cell equivalents could be detected. Tyrosinase and
MART-1 was detected with real-time PCR in all samples which
were 4 times consistently positive for tyrosinase or MART-1
(Figure 5), whereas the number of cases which were detected only
1–3 times, were detected less often (Figure 5). It is apparent that
the amount of SK-MEL-28 cell equivalents is very low: just above
1 in the case of tyrosinase and approximately 10 in the case of
MART-1 in the scatter column with 4 times a positive reaction.
These SK-MEL-28 cell equivalents were not corrected for differ-
ences in Ct of the housekeeping gene PBGD.
DISCUSSION
When reviewing the literature on the detection of circulating
melanoma cells with use of the tyrosinase PCR, with one recent
exception (Farthmann et al, 1998), no previous study has
addressed the reproducibility of PCR results. Before such PCR
will be applied in a clinical setting and before treatment decisions
will be based on its outcome, it is of vital importance to have an
understanding of how easily the PCR technique with its binary
(yes or no) answers can be reproduced when using the same
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Figure 5 Number of SK-MEL-28 cell equivalents in tyrosinase A and MART-1 (B) quantitative PCR. The results are displayed according to how often
tyrosinase and MART-1 were detected in a sample in the conventional nested PCR. Forty-seven samples were tested, including all samples which were at least
once positive (for corresponding numbers: see Table 5) after nested PCR (Table 5). Note that the results are displayed on a logarithmic Y-scale and that
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nucleic acid preparation. In the present study we addressed this
aspect of reproducibility in depth. We performed four PCRs for
tyrosinase and four PCRs for MART-1 on each of the 106 blood
samples from melanoma patients and found that in a considerable
percentage (16% and 27% for tyrosinase and MART-1 respec-
tively) of the 106 samples, no consistent result could be obtained
(the categories 1–3 in Table 5). In a recent study, similar results
were found: 33 out of 123 blood samples (27%) were 1, 2, or 3
times positive after four tyrosinase determinations (Farthmann et
al, 1998). Low consistency was also found by Jung et al who
repeatedly performed RT-PCRs for carcinoembryonic antigen in
blood samples from patients with breast cancer (Jung et al, 1997).
In the present study, we investigated the source of this inconsis-
tency using a quantitative PCR. We showed that the quality and
amplifiability of the low copy household gene PBGD mRNA was
not different in the five groups (0, 1, 2, 3, 4 times positive) for both
tyrosinase and MART-1. Furthermore, the PBGD quantitative
PCR taught us that PCRs are highly reproducible. This is mean-
ingful, since a repetition of a RT-PCR using the same RNA sample
inevitably means a difference in two enzyme (reverse transcriptase
and TAQ polymerase) and chemical mixtures. Worrying, however,
is the large range of PBGD Ct values: values between 32 and 40
cycles were found. In a PCR with an efficiency of 1, this means
that differences of 28 or 256, arise using 100 ng RNA as measured
with optical density. This means that either some RNA was
degraded in the samples with a Ct of 40 compared to samples with
a Ct of 32, or that differences of PCR inhibitory factors exist
between the samples. Furthermore, since 2 mg of nucleic acid were
used in each RT-reaction, differences in genomic DNA percent-
ages in the nucleic acid solution after RNA extraction can also
account for the large range of Ct values. Samples with substantial
amounts of DNA can give rise to lower Ct values for PBGD.
With a quantitative PCR for tyrosinase and MART-1, we found
very low numbers of SK-MEL-28 cell equivalents in the inconsis-
tently (1–3 times positive) positive samples and higher number of
SK-MEL-28 cell equivalents in the samples which were consis-
tently (4 times) positive. Theoretically, as explained by Jung et al
(1997), the reproducibility of a positive RT-PCR result in a sample
with marker molecules present at a certain density l is dependent
on this density. At low densities of target molecules present, the
probability of reproducing the positive finding of the first determi-
nation is low. We confirmed this theoretical approach in our study
using a quantitative PCR for tyrosinase and MART-1. Those
samples in which a positive result was detected, zero to three tests
had a lower number of SK-MEL-28 cell equivalents compared
with samples in which all four tests were positive. Thus, enough
target molecules should be present in a sample to allow repro-
ducible results. In case of low densities of target molecules, the
binary (yes or no) answer of the PCR will remain a matter of prob-
ability. In an earlier attempt to quantitate circulating melanoma
cells according to SK-MEL-28 cell equivalents using a tyrosinase
PCR and Southern blotting, similar SK-MEL-28 cell equivalents
were found by Brossart et al (1995). In this study, relative quantity
of tumour cells correlated with response to treatment. In addition,
the same group found in this (Brossart et al, 1995) and in previous
studies (Brossart et al, 1993, 1994) higher percentages of tyrosi-
nase PCR-positive stage IV patients, incidentally reached by
others (Mellado et al, 1996), but not in the majority of studies
using tyrosinase PCR to detect circulating melanoma cells
(Battayani et al, 1995; Foss et al, 1995; Hoon et al, 1995; Kunter et
al, 1996; Pittman et al, 1996; Stevens et al, 1996; Ghossein et al,
1998; Glaser et al, 1997; Jung et al, 1997; Reinhold et al, 1997;
Farthmann et al, 1998). Apart from technical differences among
groups who use the tyrosinase PCR for the detection of circulating
melanoma cells, differences in number of stage IV PCR-positive
melanoma patients can be explained by differences in stage IV
patients among the groups. It was recently found that positive
tyrosinase results were less frequently observed in treated stage IV
patients compared to untreated stage IV patients (U Keilholz,
personal communication, manuscript in preparation). A large
proportion of the stage IV patients in our study were included after
a treatment regiment was applied. We previously described that
tyrosinase and MART-1 are heterogeneously expressed in
melanoma metastases, with approximately 17% of the metastases
being negative for tyrosinase or MART-1 in immunohistochem-
istry (De Vries et al, 1997), this could account for some of the false
negative results.
Apart from the quantitative quality control approach of PCR,
another new aspect of our study is the use of MART-1 RT-PCR in
the detection of melanoma cells. We show that the MART-1 PCR
is more sensitive than the broadly used tyrosinase PCR in the
detection of circulating melanoma cells. Furthermore, usage of
more than one marker (in this study tyrosinase and MART-1),
increases the sensitivity of the assay, a finding confirmed in an
earlier report (Hoon et al, 1995).
Our results suggest that in stage III melanoma a positive test for
melanoma cells may help to identify patients who are at risk for
relapse. However, it should be noted that the number of stage III
patients was small and that longer follow-up is needed. Also, a
possible bias is introduced by the availability of different number
of samples from stage III patients (13 patients, 27 samples).
We agree with the caution that has been advocated for the appli-
cation of melanoma marker PCRs for clinical use (Buzaid and
Balch, 1996; Glaser et al, 1997; Reinhold et al, 1997). Clearly, it
has been shown convincingly by various groups that the likelihood
of detection increases with stage of disease, but differences in
sensitivity reached by the various laboratories will seriously
hamper the use of melanoma marker PCR in routine clinical prac-
tice. In our view, the introduction of a stringent quality control
regime using a quantitative low copy household gene PCR for the
amplifiability of mRNA, amplifiability of low copy numbers of
target mRNA, repetitions of positive and negative results, and
introduction of multiple markers are mandatory when tests for
circulating tumour cells are applied to clinical decision-making.
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